Updated interim data from Ph 1/2 study of ozekibart (INBRX-109) + FOLFIRI in patients with metastatic CRC announced April 28, 2026
Positive PDS01ADC Interim Ph 2 Trial Data from Stage 1 of NCI-led Metastatic CRC Trial Published April 21, 2026
Adagene and Incyte to Evaluate Muzastotug (ADG126) in Combination with INCA33890 in Patients with MSS CRC April 15, 2026
Updated Data from Ph 1b/2 Study of Muzastotug + KEYTRUDA in Late-line Patients with MSS CRC Demonstrate Improved Durability of Response April 15, 2026
Positive Ph 1 expansion data for EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC announced March 24, 2026
FDA approves IND application for KST-0651 for Ph 1 trial in Advanced Solid Tumors including pancreatic cancer, CRC, NSCLC, and others March 10, 2026
Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
FDA Accepted NDA for Zanzalintinib – Tecentriq Combo in Patients with Metastatic CRC February 9, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 9, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat CRC January 18, 2026
BRAFTOVI® Regimen with Additional Chemo Backbone Increased Response Rates for Certain Patients with Metastatic CRC January 11, 2026
Strong Topline Ph 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in CRC Announced January 11, 2026
